Opendata, web and dolomites

LEGACy SIGNED

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LEGACy project word cloud

Explore the words cloud of the LEGACy project. It provides you a very rough idea of what is the project "LEGACy" about.

treatments    outcomes    vary    deaths    respectively    gastric    patients    prevention    sexes    dietary    10    standpoint    differences    makeup    legacy    eastern    death    rates    south    celac    public    ebv       virus    worldwide    723    medicine    genome    globally    model    histological    levels    cancer    molecular    strategies    databases    men    intervention    incidence    pylori    infection    omics    similarly    integrative    women    america    asia    24    epidemiology    sharp    biology    international    largely    conceptual    barr    total    multiple    revolutionized    health    countries    epstein    primary    northern    gc    highest    arrival    gcs    personalized    stage    extended    strains    prognosis    tumour    disease    susceptibility    location    central    lowest    bacterium    multicentre    secondary    positive    asian    participating    contrast    strategy    mortality    poorly    none    urgent    locally    epidemiological    genetic    helicobacter    populations    plays   

Project "LEGACy" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA 

Organization address
address: AV MENENDEZ PELAYO 4
city: VALENCIA
postcode: 46010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙993˙056 €
 EC max contribution 3˙577˙431 € (90%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEGACY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEGACY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More